Evidence map›Paper›PMID 29520722›Full record

ArticleNeurotoxicity research2018

Human Umbilical Cord Matrix Stem Cells Reverse Oxidative Stress-Induced Cell Death and Ameliorate Motor Function and Striatal Atrophy in Rat Model of Huntington Disease.

Mohammad Javad Ebrahimi, Abbas Aliaghaei, Mahdi Eskandarian Boroujeni, Fariba Khodagholi, Gholamhoussein Meftahi, Mohammad Amin Abdollahifar, Houssein Ahmadi, Samira Danyali, Mahtab Daftari, Yousef Sadeghi

Abstract read
PubMed Publisher
In one paragraph

Article in Neurotoxicity research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Current and Possible Future Therapeutic Options for Huntington's Disease.Journal of central nervous system disease · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Mohammad Javad EbrahimiCell Biology and Anatomical Sciences, School Of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abbas AliaghaeiCell Biology and Anatomical Sciences, School Of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mahdi Eskandarian BoroujeniDepartment Of Stem Cells and Rgenerative Medicine, Faculty of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Fariba KhodagholiNeuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Gholamhoussein MeftahiNeuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Mohammad Amin AbdollahifarCell Biology and Anatomical Sciences, School Of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Houssein AhmadiCell Biology and Anatomical Sciences, School Of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Samira DanyaliNeurophysiology Research Center, Shahid Beheshti University Of Medical Sciences, Tehran, Iran.
Mahtab DaftariNeuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Yousef SadeghiCell Biology and Anatomical Sciences, School Of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. dr.ysadeghi@yahoo.com.
Shahid Beheshti University of Medical Sciences · IRBaqiyatallah University of Medical Sciences · IRNational Institute of Genetic Engineering and Biotechnology · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Huntington disease (HD) is an inherited disorder hallmarked by progressive deterioration of specific neurons, followed by movement and cognitive anomalies. Cell therapy approaches in neurodegenerative conditions have concentrated on the replenishment of lost/dying neurons with functional ones. Multipotent mesenchymal stem cells (MSCs) have been represented as a potential remedy for HD. In this study, we evaluated the in vitro and in vivo efficacy of umbilical cord matrix stem cells (UCMSCs) and their paracrine effect against oxidative stress with a specific focus on HD. To this end, UCMSCs were isolated, immunophenotypically characterized by the positive expression of MSC markers, and exhibited multilineage potentiality. Besides, synthesis of neurotrophic factors of GDNF and VEGF by UCMSC was confirmed. Initially, PC12 cells were exposed to superoxide in the presence of conditioned media (CM) collected from UCMSC (UCMSC-CM) and cell viability plus neuritogenesis were measured. Next, bilateral striatal transplantation of UCMSC in 3-nitropropionic acid (3-NP) lesioned rat models was conducted, and 1 month later, post-graft analysis was performed. According to our in vitro results, CM of UCMSC protected PC12 cells against oxidative stress and considerably enhanced cell viability and neurite outgrowth. On the other hand, transplanted UCMSC survived, decreased gliosis, and ameliorated motor coordination and muscle activity, along with an increase in striatal volume as well as in dendritic length of the striatum in HD rats. Collectively, our findings imply that UCMSCs provide an enriched platform by largely their paracrine factors, which downgrades the unfavorable effects of oxidative stress.

Indexed as

Huntington DiseaseAnimalsAntigens, CDCell DeathCell DifferentiationCell LineConvulsantsCord Blood Stem Cell TransplantationCorpus StriatumDendritesDisease Models, AnimalElectromyographyGlial Cell Line-Derived Neurotrophic FactorGlial Fibrillary Acidic ProteinGliosisHumans3-nitropropionic acidAntigens, CDConvulsantsGlial Cell Line-Derived Neurotrophic FactorGlial Fibrillary Acidic ProteinHydrogen PeroxideNitro CompoundsOxidantsPropionatesVascular Endothelial Growth Factor ACell therapyHuntington diseaseMesenchymal stem cellsUmbilical cord

Identifiers

PMID29520722
OpenAlexW2793018077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.